MYD88 and diffuse large B-cell lymphoma: Mutations of genes associated with NF-κB activation (e.g., PRDM1, TNFAIP3, MYD88, TBL1XR1) or the B-cell receptor signaling pathway (e.g., CD79b and CARD11) could also lead to increased MYC expression in a subset of CNS DLBCL [3], [24], [27], [28].